drugset / Trial / NCT00825565
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Phase 2
Completed
8 enrolled
Northwestern University
Ann & Robert H Lurie Children's Hospital of Chicago · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.
Timeline
- Start
- 2009-02
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allantoin | Small molecule | 3 % | Topical |